BriaCell Therapeutics Cor...

5.16
0.97 (23.15%)
At close: Apr 22, 2025, 3:59 PM
4.48
-13.09%
After-hours: Apr 22, 2025, 06:32 PM EDT

Company Description

BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer.

Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer.

The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test.

BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.

BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp. logo
Country CA
IPO Date Mar 14, 2012
Industry Biotechnology
Sector Healthcare
Employees 16
CEO Dr. William V. Williams M.D.

Contact Details

Address:
Bellevue Centre
West Vancouver, BC
CA
Website https://www.briacell.com

Stock Details

Ticker Symbol BCTX
Exchange NASDAQ
Fiscal Year August - July
Reporting Currency USD
CIK Code 0001610820
CUSIP Number 10778Y302
ISIN Number CA1079301091
Employer ID 00-0000000
SIC Code 2834

Key Executives

Name Position
Dr. William V. Williams M.D. Chief Executive Officer, President & Director
Gadi Levin B.Com., C.A., CPA, M.B.A. Chief Financial Officer & Corporate Secretary
Dr. Charles Louis Wiseman FACP, M.D. Founder, Principal Research Advisor & Member of Scientific Advisory Board
Dr. Giuseppe Del Priore M.D., M.P.H., MPH Chief Medical Officer
Dr. Miguel A. Lopez-Lago Ph.D. Chief Scientific Officer

Latest SEC Filings

Date Type Title
Mar 12, 2025 10-Q Quarterly Report
Mar 12, 2025 8-K Current Report
Feb 13, 2025 8-K Current Report
Feb 10, 2025 SCHEDULE 13G Filing
Feb 06, 2025 8-K Current Report
Feb 05, 2025 8-K Current Report
Feb 04, 2025 424B5 Filing
Feb 03, 2025 424B5 Filing
Jan 28, 2025 8-K Current Report
Jan 03, 2025 8-K Current Report